
<!DOCTYPE html>
<html  lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<script async src="https://www.googletagmanager.com/gtag/js?id=G-273DTKB5QW"></script>
<meta name="description" content="Guidance documents represent the FDA&#039;s current thinking on a particular subject. New guidance documents are listed here for three months." />
<meta name="dcterms.title" content="Newly Added Guidance Documents" />
<meta name="dcterms.creator" content="Center for Drug Evaluation and Research" />
<meta name="dcterms.description" content="Guidance documents represent the FDA&#039;s current thinking on a particular subject. New guidance documents are listed here for three months." />
<meta name="dcterms.publisher" content="FDA" />
<meta name="dcterms.type" content="Article" />
<meta name="dcterms.source" content="FDA" />
<meta property="og:site_name" content="U.S. Food and Drug Administration" />
<meta property="og:type" content="Article" />
<meta property="og:url" content="https://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents" />
<meta property="og:title" content="Newly Added Guidance Documents" />
<meta property="og:description" content="Guidance documents represent the FDA&#039;s current thinking on a particular subject. New guidance documents are listed here for three months." />
<meta property="og:updated_time" content="Mon, 02/05/2024 - 00:00" />
<meta property="article:publisher" content="FDA" />
<meta property="article:published_time" content="Mon, 02/05/2024 - 13:33" />
<meta property="article:modified_time" content="Mon, 02/05/2024 - 00:00" />
<meta name="google-site-verification" content="tWxlDhm4ANdksJZPj7TBmHgNoMqZCnecPp0Aa2vC9XA" />
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:site" content="@US_FDA" />
<meta property="twitter:description" content="Guidance documents represent the FDA&#039;s current thinking on a particular subject. New guidance documents are listed here for three months." />
<meta name="twitter:title" content="Newly Added Guidance Documents" />
<meta name="twitter:creator" content="@US_FDA" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<script type="application/ld+json">{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "Article",
            "headline": "Newly Added Guidance Documents",
            "name": "Newly Added Guidance Documents",
            "description": "Guidance documents represent the FDA\u0027s current thinking on a particular subject. New guidance documents are listed here for three months.",
            "image": {
                "@type": "ImageObject",
                "representativeOfPage": "True"
            },
            "datePublished": "Mon, 02/05/2024 - 13:33",
            "dateModified": "Mon, 02/05/2024 - 00:00",
            "author": {
                "@type": "Organization",
                "name": "Center for Drug Evaluation and Research"
            },
            "publisher": {
                "@type": "Organization",
                "name": "FDA"
            }
        }
    ]
}</script>
<meta property="og:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<meta name="twitter:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<link rel="icon" href="/themes/custom/preview/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents" />
<link rel="canonical" href="https://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents" />
<link rel="shortlink" href="https://www.fda.gov/node/386734" />
<script src="/files/google_tag/production/google_tag.script.js?s8kd7q" defer></script>

    <title>Newly Added Guidance Documents | FDA</title>
    <link rel="stylesheet" media="all" href="/files/css/css_iqq3a5TSnaKHverAjiNiEaOZLAijh7RZOh1mLW7SWlE.css?delta=0&amp;language=en&amp;theme=preview&amp;include=eJxlUNFuwyAM_CFS9jJpf4MccCgacAy7rdKvX7JqNN1kyTrdyb6zl0COM74uZJcBzYKqdGNBYXvAJxOBmNlRpbxq8mL_EkZWUS52JmHTOl8T32zMmClPomtONf6jfU9NxcyAinZqtqHhyt3sifwnh6TojuuZqufCVcWS9-ghoTpF3APIGV09wtN0G54C6VZzZnmhf3ce9V0U-9NPBeGS-WGP0nLajR-ae3_7OJDbp6AVymIHGla-033l-Dw4UHuJOEJP455vZX-dMw" />
<link rel="stylesheet" media="all" href="/files/css/css_5A0fSLvl8VSdnAAvAtivTPfg3E4W6aT1UwUZLMadWyc.css?delta=1&amp;language=en&amp;theme=preview&amp;include=eJxlUNFuwyAM_CFS9jJpf4MccCgacAy7rdKvX7JqNN1kyTrdyb6zl0COM74uZJcBzYKqdGNBYXvAJxOBmNlRpbxq8mL_EkZWUS52JmHTOl8T32zMmClPomtONf6jfU9NxcyAinZqtqHhyt3sifwnh6TojuuZqufCVcWS9-ghoTpF3APIGV09wtN0G54C6VZzZnmhf3ce9V0U-9NPBeGS-WGP0nLajR-ae3_7OJDbp6AVymIHGla-033l-Dw4UHuJOEJP455vZX-dMw" />

    <script src="https://script.crazyegg.com/pages/scripts/0024/3700.js" async></script>
<script src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&amp;subagency=FDA&amp;sdor=fda.gov&amp;dclink=true" language="javascript" id="_fed_an_ua_tag"></script>

            <script>window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag("js", new Date());gtag("set", "developer_id.dMDhkMT", true);gtag("config", "G-273DTKB5QW", {"groups":"default","page_placeholder":"PLACEHOLDER_page_location","allow_ad_personalization_signals":false});</script>
        
  </head>
  <body class="role-anonymous path-node page-node-type-article has-glyphicons">
      <div id="quicklinks" class="sr-only">
        <ul>
          <li><a href="#main-content" class="sr-only sr-only-focusable" tabindex="1">Skip to main content</a></li>
          <li><a href="#search-form" class="sr-only sr-only-focusable" tabindex="1">Skip to FDA Search</a></li>
          <li><a href="#section-nav" class="sr-only sr-only-focusable" tabindex="1">Skip to in this section menu</a></li>
          <li><a href="#footer-heading" class="sr-only sr-only-focusable" tabindex="1">Skip to footer links</a></li>
        </ul>   
      </div>    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M95XGZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
       
  <div class="main-container container-fluid">     <div class="row">
                                                               


	
	<header class="lcds-header container-fluid" role="heading" aria-level="1">
		                    			<div class="row us-masthead">                            

				<div class="usa-banner col-xs-12">

					<img class="usa-banner__us-flag" src="/themes/custom/preview/assets/images/US_Flag.png" alt="U.S. flag" />

					<span>An official website of the United States government</span>

					<a id="USMenuButton" class="collapsed" data-toggle="collapse" data-target="#USABannerMenu" aria-controls="USABannerMenu">Here’s how you know <span class="toggle-indicator"> </span></a>
          			<div class="col-xs-12 collapse usa-banner__menu" id="USABannerMenu" aria-labelledby="USMenuButton">


						<div id="gov-banner" class="row usa-banner-content usa-grid usa-accordion-content" aria-hidden="true">
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-dot-gov.svg" alt="Dot gov" style="width:3em;">
									<div class="usa-media_block-body">
								      <p><strong>The .gov means it’s official.</strong><br>Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.</p>
								    </div>
							      </div>
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-https.svg" alt="SSL" style="width:3em;">
							        <div class="usa-media_block-body">
								         <p><strong>The site is secure.</strong><br> The <strong>https://</strong> ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.</p>
							        </div>
							      </div>
						</div>
					</div>

				</div>
			</div> 
			<div class="row fda-masthead">
							<div class="col-xs-4 col-md-8"> 
					<a href="/" title="FDA Homepage">
						<h1 class="fda-masthead__fda-logo">U.S. Food and Drug Administration</h1>
					</a>
       	</div>
				
        <div class="col-xs-8 col-md-4">
          <ul class='fda-masthead__item-list'>
            <li><a title="" id="btn-search" class="btn btn-default btn-sm fda-masthead__btn-search">
              <span class="fa fa-search" aria-hidden="true">&nbsp;</span>
              <span class="fda-masthead__btn-label">Search</span>
            </a></li>
            <li><a id="menu-btn" class="btn btn-default btn-sm fda-masthead__btn-menu collapsed" href="#primary-nav" data-toggle="collapse" aria-expanded="true">
              <span class="fa fa-bars" aria-hidden="true">&nbsp;</span>
              <span class='fda-masthead__btn-label'>Menu</span>
            </a></li>
          </ul>
				</div>
							
						<form class="fda-masthead__search sr-only" role="search" action="/search" method="GET" name="searchForm" id="search-form" accept-charset="UTF-8" >
							
							<div class="search-popover" id="search-popover">
								<div class="input-group pull-right" id="search-group">
									<label class="sr-only" for="search-query">Search FDA</label>
									
									<input class="form-control search-input" id="search-query" name="s" aria-autocomplete="list" aria-haspopup="true" title="Enter the terms you wish to search for." placeholder="Search FDA"  type="text" /> 
									
									<span class="input-group-btn" id="input-group-btn">
										
										<button type="submit" class="btn btn-danger search-btn" id="search-btn" title="Search"><span class="fa fa-search" aria-hidden="true"><span class="sr-only">Submit search</span></span></button>

									</span>

								</div>
							</div>
																				
						</form>					

			</div> 
		<nav id="primary-nav" class="lcds-primary-nav row collapse">					<div class="col-md-5 col-lg-4">
						<section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
							<h2 class="lcds-primary-nav__group-heading">Featured</h2>
							<ul class="lcds-primary-nav__list lcds-primary-nav__list--featured">
	                <li class="lcds-primary-nav__list-item"><a href="/about-fda/contact-fda">Contact FDA</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/regulatory-information/search-fda-guidance-documents">FDA Guidance Documents</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/safety/recalls-market-withdrawals-safety-alerts">Recalls, Market Withdrawals and Safety Alerts</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/news-events/newsroom/press-announcements">Press Announcements</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/advisory-committees">Advisory Committees</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/about-fda/en-espanol">En Espa&#241ol</a></li>
							</ul>
						</section>
					</div>

					<div class="col-md-7 col-lg-8">
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Products</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/food">Food</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/drugs">Drugs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/medical-devices">Medical Devices</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/radiation-emitting-products">Radiation-Emitting Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/vaccines-blood-biologics">Vaccines, Blood, and Biologics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/animal-veterinary">Animal and Veterinary</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/cosmetics">Cosmetics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/tobacco-products">Tobacco Products</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Topics</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/about-fda">About FDA</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/combination-products">Combination Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/regulatory-information">Regulatory Information</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/safety">Safety</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/emergency-preparedness-and-response">Emergency Preparedness</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/international-programs">International Programs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/news-events">News and Events</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/training-and-continuing-education">Training and Continuing Education</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections and Compliance</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/science-research">Science and Research</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Information For</h2>
            <ul class="lcds-primary-nav__list">
	            <li class="lcds-primary-nav__list-item"><a href="/consumers">Consumers</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/patients">Patients</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/industry">Industry</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/health-professionals">Health Professionals</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/federal-state-local-tribal-and-territorial-officials">Federal, State and Local Officials</a></li>
            </ul>
          </section>
					</div>
	      </nav>
    </header>

<div class="col-xs-12">
	<div data-drupal-messages-fallback class="hidden"></div>

</div>

                              
                                                                     <section id="block-entityviewcontent" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

<a class="lcds-button--expandable collapsed hidden-md hidden-lg" data-toggle="collapse" href="#section-nav" >In this section<span class="visible-sm-inline-block">:

                Guidances | Drugs
    
    </span>
</a>

<nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav hidden-md hidden-lg collapse">

    <ul class="lcds-section-nav__list">

      <li>

              <a href="/drugs/guidance-compliance-regulatory-information/guidances-drugs" title="Guidances | Drugs" class="lcds-section-nav__section-link lcds-section-nav__link lcds-section-nav__parent-link visible-xs-block visible-sm-block">
                                        Guidances | Drugs
                    </a>

                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_5 js-view-dom-id-a17026f7cb5096a6a03fc0378e9500c8b7a2543a8172a0e9249c89993220541f">
  
    
      
  
      <div>
  
  <ul class="lcds-section-nav__section-link__active lcds-section-nav__list">

          <li><a href="/drugs/guidances-drugs/product-specific-guidances-generic-drug-development" class="lcds-section-nav__link">Product-Specific Guidances for Generic Drug Development</a></li>
          <li><a href="/drugs/guidances-drugs/guidance-snapshot-pilot" class="lcds-section-nav__link">Guidance Snapshot Pilot</a></li>
    
  </ul>

</div>


  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_2 js-view-dom-id-fed201b3572d182a9723351ac73d6e892a543be6d0c0a0772090a483eb68943f">
  
    
      
  
          </div>
</div>


      </li>

    </ul>

</nav>

  </section>

<section id="block-entityviewcontent-15" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
    <ol class="lcds-breadcrumb visible-md visible-lg">
          <li >
                  <a href="/">Home</a>
              </li>
          <li >
                  <a href="/drugs">Drugs</a>
              </li>
          <li >
                  <a href="/drugs/guidance-compliance-regulatory-information">Guidance, Compliance, &amp; Regulatory Information</a>
              </li>
          <li >
                  <a href="/drugs/guidance-compliance-regulatory-information/guidances-drugs">Guidances | Drugs</a>
              </li>
          <li >
                  <a class="current-link">Newly Added Guidance Documents</a>
              </li>
      </ol>




<ol class="lcds-breadcrumb visible-sm visible-xs">
  <li>
    <a href="/drugs/guidance-compliance-regulatory-information/guidances-drugs" title="Guidances | Drugs">
     Guidances | Drugs
    </a>
  </li>
</ol>

  </section>






                                
      <main>

                                 <article id="main-content" class="article main-content container-fluid" role="article">
          
                                                                <header class="row content-header" role="heading" aria-level="1">
                         <section id="block-entityviewcontent-2" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="col-sm-12 col-md-8 col-md-offset-2">

  <h1 class="content-title text-center">Newly Added Guidance Documents</h1>
  
  	
    <div class="lcds-toolbar lcds-toolbar--social">
      <ul class="lcds-share lcds-share--default">
    <li class="lcds-share__item">
      <a href="https://www.facebook.com/sharer/sharer.php?u=https://www.fda.gov%2Fdrugs%2Fguidances-drugs%2Fnewly-added-guidance-documents" class="lcds-share__btn lcds-share--default__btn-facebook js-share" id="fb-share" target="_blank"><span class="fa icon-facebook" aria-hidden="true"></span>Share</a>
    </li>
    <li class="lcds-share__item">
      <a href="https://x.com/intent/tweet/?text=Newly%20Added%20Guidance%20Documents&amp;url=https://www.fda.gov%2Fdrugs%2Fguidances-drugs%2Fnewly-added-guidance-documents" target="_blank" class="lcds-share__btn lcds-share--default__btn-x-twitter js-share" id="twitter-share">
        <svg class="icon-svg-inline" aria-hidden="true">
          <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter">
        </svg>
        Post
      </a>
    </li>
    <li class="lcds-share__item hidden-xs">
      <a href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.fda.gov%2Fdrugs%2Fguidances-drugs%2Fnewly-added-guidance-documents&amp;title=Newly%20Added%20Guidance%20Documents&amp;source=FDA" class="lcds-share__btn lcds-share--default__btn-linkedin js-share" id="linkedin-share" target="_blank"><span class="fa icon-linkedin" aria-hidden="true"></span>Linkedin</a>
    </li>

    <li class="lcds-share__item">
      <a href="mailto:?subject=Newly%20Added%20Guidance%20Documents&amp;body=https://www.fda.gov%2Fdrugs%2Fguidances-drugs%2Fnewly-added-guidance-documents" class="lcds-share__btn lcds-share--default__btn-mail"><span class="fa icon-envelope" aria-hidden="true"></span>Email</a>
      </li>
    <li class=" lcds-share__item hidden-xs">
      <a href="javascript:window.print();" title="Print this page" class="lcds-share__btn lcds-share--default__btn-print"><span class="fa icon-print" aria-hidden="true"></span>Print</a>
    </li>
  </ul>
  <div class="form-group">
    
  </div>
</div>
 
</div>

  </section>






                      </header>
                              
                                                                           <div class="col-md-8 col-md-push-2" role="main">

                            
                            
                            
                            
                                              
  
<p>Below is a sortable list of the most recently added Guidance Documents.</p>

<p>You can sort alphabetically by: Category/Subject Area; Guidance Title; Guidance Type (Draft or Final) and also sort by the Date the Guidance was issued.</p>

<h2>Newly Added Guidance Documents</h2>

<div class="lcds-datatable lcds-datatable--ckeditor">
<table class="table table-striped" data-column-defs="[{ &quot;targets&quot;: 3, &quot;type&quot;: &quot;date&quot; }]" data-excel-button="true" data-order="[ 3, &quot;desc&quot; ]" data-paging="true" data-searching="true" summary="Newly Added Guidances"><thead><tr><th scope="col">Topic</th>
			<th scope="col">Guidance</th>
			<th scope="col">Status</th>
			<th scope="col">Date</th>
		</tr></thead><tbody><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="768958d2-f64c-4ed2-b290-bf499646dce7" href="/regulatory-information/search-fda-guidance-documents/notifying-fda-discontinuance-or-interruption-manufacturing-finished-products-or-active" title="Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&amp;C Act">Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&amp;C Act</a></td>
			<td>Draft</td>
			<td>2/06/2024</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="438f2199-9741-4c7f-a40d-7939794a727e" href="/regulatory-information/search-fda-guidance-documents/reporting-amount-listed-drugs-and-biological-products-under-section-510j3-fdc-act" title="Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&amp;C Act">Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&amp;C Act</a></td>
			<td>Final</td>
			<td>2/05/2024</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b09184be-f815-4830-8289-0ebffb63cc50" href="/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical" title="Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products">Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products</a></td>
			<td>Draft</td>
			<td>1/30/2024</td>
		</tr><tr><td>Generic Drugs</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a5f0d4ad-0102-4c51-bc04-e32889643af4" href="/regulatory-information/search-fda-guidance-documents/revising-anda-labeling-following-revision-rld-labeling-guidance-industry" title="Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry">Revising ANDA Labeling Following Revision of the RLD Labeling Guidance for Industry</a></td>
			<td>Final</td>
			<td>1/24/2024</td>
		</tr><tr><td>
			<p>Generic Drugs</p>
			</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8409182c-e9ae-41e5-85d6-391cbf25e24e" href="/regulatory-information/search-fda-guidance-documents/requests-reconsideration-division-level-under-gdufa" title="Requests for Reconsideration at the Division Level Under GDUFA">Requests for Reconsideration at the Division Level Under GDUFA</a></td>
			<td>Draft</td>
			<td>1/10/2024</td>
		</tr><tr><td>
			<p>ICH-Quality</p>
			</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6f1f6ceb-e7ef-4d42-9748-6be9ad7e1c6d" href="/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin" title="Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin">Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin</a></td>
			<td>Final</td>
			<td>1/10/2024</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0501624f-55a5-4f20-9f53-c59c69e6e7d7" href="/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene" title="Reformulating Drug Products That Contain Carbomers Manufactured With Benzene">Reformulating Drug Products That Contain Carbomers Manufactured With Benzene</a></td>
			<td>Final</td>
			<td>12/28/2023</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c9119b68-a6c8-46d2-9cd2-c3598a46984e" href="/regulatory-information/search-fda-guidance-documents/quality-considerations-topical-ophthalmic-drug-products" title="Quality Considerations for Topical Ophthalmic Drug Products">Quality Considerations for Topical Ophthalmic Drug Products</a></td>
			<td>Draft</td>
			<td>12/27/2023</td>
		</tr><tr><td>Advertising</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="eae1df82-ce38-40ea-b07f-cd86b47389b2" href="/regulatory-information/search-fda-guidance-documents/direct-consumer-prescription-drug-advertisements-presentation-major-statement-clear-conspicuous-and" title="Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers">Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers</a></td>
			<td>Final</td>
			<td>12/26/2023</td>
		</tr><tr><td>Rare Diseases</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="addab0e0-7d47-4ba6-acb3-ca6825d30195" href="/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products" title="Rare Diseases: Considerations for the Development of Drugs and Biological Products">Rare Diseases: Considerations for the Development of Drugs and Biological Products</a></td>
			<td>Final</td>
			<td>12/26/2023</td>
		</tr><tr><td>Real World Data / Real World Evidence (RWD/RWE), Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="56f95484-ca36-4446-8214-8c6afa141113" href="/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data" title="Data Standards for Drug and Biological Product Submissions Containing Real-World Data">Data Standards for Drug and Biological Product Submissions Containing Real-World Data</a></td>
			<td>Final</td>
			<td>12/22/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e145ad98-149e-4576-9796-0ebc86e6de57" href="/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations" title="Digital Health Technologies for Remote Data Acquisition in Clinical Investigations">Digital Health Technologies for Remote Data Acquisition in Clinical Investigations</a></td>
			<td>Final</td>
			<td>12/22/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="33de4bd5-ffe8-4b50-b1d5-09654b8a4109" href="/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products" title="Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products">Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products</a></td>
			<td>Final</td>
			<td>12/22/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b88d3b6b-9668-438a-a13c-3210af4c710b" href="/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development" title="Master Protocols for Drug and Biological Product Development">Master Protocols for Drug and Biological Product Development</a></td>
			<td>Draft</td>
			<td>12/21/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4e9870b5-16d7-412f-9a37-54b5646b5c73" href="/regulatory-information/search-fda-guidance-documents/development-monoclonal-antibody-products-targeting-sars-cov-2-emergency-use-authorization" title="Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization">Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization</a></td>
			<td>Final</td>
			<td>12/21/2023</td>
		</tr><tr><td>Compounding</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="29c21fea-c132-4e64-879f-8d8e28243d86" href="/regulatory-information/search-fda-guidance-documents/advanced-manufacturing-technologies-designation-program" title="Advanced Manufacturing Technologies Designation Program">Advanced Manufacturing Technologies Designation Program</a></td>
			<td>Draft</td>
			<td>12/13/2023</td>
		</tr><tr><td>Compounding</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6744f8a6-ebed-40ee-b4d2-01b6485639d8" href="/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and-0" title="Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2">Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2</a></td>
			<td>Draft</td>
			<td>12/06/2023</td>
		</tr><tr><td>Compounding</td>
			<td><a data-e="" data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5268c455-6840-4b19-bc79-559a93c672cb" href="/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and-0" title="Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act">Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Draft</td>
			<td>12/06/2023</td>
		</tr><tr><td>Compounding</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6744f8a6-ebed-40ee-b4d2-01b6485639d8" href="/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503b-federal-food-drug-and-0" title="Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2">Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act - Revision 2</a></td>
			<td>Draft</td>
			<td>12/06/2023</td>
		</tr><tr><td>Pharmacology/Toxicology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d5edc28f-866c-4005-83b0-0d5ed689511e" href="/regulatory-information/search-fda-guidance-documents/translation-good-laboratory-practice-study-reports-questions-and-answers" title="Translation of Good Laboratory Practice Study Reports: Questions and Answers">Translation of Good Laboratory Practice Study Reports: Questions and Answer</a></td>
			<td>Draft</td>
			<td>11/21/2023</td>
		</tr><tr><td>Technical Specifications Document</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="dfc4b11f-8e63-49e2-bd7d-21f4d7a93d03" href="/regulatory-information/search-fda-guidance-documents/submitting-patient-reported-outcome-data-cancer-clinical-trials" title="Submitting Patient-Reported Outcome Data in Cancer Clinical Trials">Submitting Patient-Reported Outcome Data in Cancer Clinical Trials</a></td>
			<td>Final</td>
			<td>11/06/2023</td>
		</tr><tr><td>Technical Specifications Document</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5553f535-d6b9-48ad-9870-dcead34da047" href="/regulatory-information/search-fda-guidance-documents/submitting-clinical-trial-datasets-and-documentation-clinical-outcome-assessments-using-item" title="Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory">Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory</a></td>
			<td>Final</td>
			<td>11/06/2023</td>
		</tr><tr><td>Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e3b0dbec-48b0-435d-a68b-caad035739d9" href="/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities" title="Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities">Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities</a></td>
			<td>Draft</td>
			<td>10/26/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8029f4f5-2cbb-4682-aedb-34f49dcf099e" href="/regulatory-information/search-fda-guidance-documents/communications-firms-health-care-providers-regarding-scientific-information-unapproved-uses" title="Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers">Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products Questions and Answers</a></td>
			<td>Draft</td>
			<td>10/24/2023</td>
		</tr><tr><td>Current Good Manufacturing Practice (CGMP)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0c1cb576-6373-470a-9cb3-a0e2d029ebec" href="/regulatory-information/search-fda-guidance-documents/policy-testing-alcohol-ethanol-and-isopropyl-alcohol-methanol" title="Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol">Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol</a></td>
			<td>Final</td>
			<td>10/17/2023</td>
		</tr><tr><td>Clinical/Antimicrobial</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bc7f4631-4c08-4a16-8b10-1c5cb4e6d01a" href="/regulatory-information/search-fda-guidance-documents/diabetic-foot-infections-developing-drugs-treatment" title="Diabetic Foot Infections: Developing Drugs for Treatment">Diabetic Foot Infections: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>10/17/2023</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c9119b68-a6c8-46d2-9cd2-c3598a46984e" href="/regulatory-information/search-fda-guidance-documents/quality-considerations-topical-ophthalmic-drug-products" title="Quality Considerations for Topical Ophthalmic Drug Products">Quality Considerations for Topical Ophthalmic Drug Products</a></td>
			<td>Draft</td>
			<td>10/13/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="adfb5c2d-b9ee-4d0c-bdd6-40f97b42f5f7" href="/regulatory-information/search-fda-guidance-documents/stimulant-use-disorders-developing-drugs-treatment" title="Stimulant Use Disorders: Developing Drugs for Treatment">Stimulant Use Disorders: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>10/05/2023</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d0fe52b9-0b19-4b65-b9ae-f251a67ebd34" href="/regulatory-information/search-fda-guidance-documents/human-prescription-drug-and-biological-products-labeling-dosing-based-weight-or-body-surface-area" title="Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”">Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”</a></td>
			<td>Final</td>
			<td>10/02/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bb3b277d-7aab-46ca-816f-368def05846e" href="/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-pdufa-products" title="Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products">Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products</a></td>
			<td>Draft</td>
			<td>9/22/2023</td>
		</tr><tr><td>Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b9b26682-8614-4942-8904-ab963be70299" href="/regulatory-information/search-fda-guidance-documents/alternative-tools-assessing-drug-manufacturing-facilities-identified-pending-applications" title="Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications">Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications</a></td>
			<td>Draft</td>
			<td>9/22/2023</td>
		</tr><tr><td>Emergencies</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b39c45e9-f73c-4014-aed8-c9c4dfdde2ae" href="/regulatory-information/search-fda-guidance-documents/considerations-conduct-clinical-trials-medical-products-during-major-disruptions-due-disasters-and" title="Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies">Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies</a></td>
			<td>Final</td>
			<td>9/21/2023</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="782c275c-e410-45da-811b-a5e31b8d4873" href="/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescription-drug-use-related-software" title="Regulatory Considerations for Prescription Drug Use-Related Software">Regulatory Considerations for Prescription Drug Use-Related Software</a></td>
			<td>Draft</td>
			<td>9/19/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4b982da6-14d5-4e87-abdd-a4fd5d6f1a0e" href="/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-one-adequate-and-well-controlled-clinical" title="Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence">Demonstrating Substantial Evidence of Effectiveness Based on One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence</a></td>
			<td>Draft</td>
			<td>9/19/2023</td>
		</tr><tr><td>Biosimilars</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3fa74271-b4d5-4e5f-b365-044a275881e6" href="/regulatory-information/search-fda-guidance-documents/biosimilarity-and-interchangeability-additional-draft-qas-biosimilar-development-and-bpci-act" title="Biosimilarity and Interchangeability:  Additional Draft Q&amp;As on Biosimilar Development and the BPCI Act (Revision 1)">Biosimilarity and Interchangeability: Additional Draft Q&amp;As on Biosimilar Development and the BPCI Act (Revision 1)</a></td>
			<td>Draft</td>
			<td>9/18/2023</td>
		</tr><tr><td>Biosimilars</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c1be7835-c8e8-425d-97e0-44d61aa50590" href="/regulatory-information/search-fda-guidance-documents/labeling-biosimilar-and-interchangeable-biosimilar-products" title="Labeling for Biosimilar and Interchangeable Biosimilar Products">Labeling for Biosimilar and Interchangeable Biosimilar Products</a></td>
			<td>Draft</td>
			<td>9/18/2023</td>
		</tr><tr><td>Food &amp; Drug Administration Modernization Act of 1997</td>
			<td>
			<p style="margin-bottom:11px"><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5caa6cb1-20d4-4152-82f7-726238c97a0f" href="/regulatory-information/search-fda-guidance-documents/annual-status-report-information-and-other-submissions-postmarketing-requirements-and-commitments" title="Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry">Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry</a></p>
			</td>
			<td>Final</td>
			<td>9/15/2023</td>
		</tr><tr><td>Clinical - Pharmacology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="34aa63d8-e455-435a-a6a2-9e98d2ce4558" href="/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-peptide-drug-products" title="Clinical Pharmacology Considerations for Peptide Drug Products">Clinical Pharmacology Considerations for Peptide Drug Products</a></td>
			<td>Draft</td>
			<td>9/11/2023</td>
		</tr><tr><td>Good Clinical Practice (GCP)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0eb51ac5-c567-494a-a1c5-15cc8cfec365" href="/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-review-individual-patient-expanded-access-submissions-investigational" title="Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products">Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products</a></td>
			<td>Final</td>
			<td>9/11/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ee3227bf-2e44-483e-8587-00570601f6cb" href="/regulatory-information/search-fda-guidance-documents/endogenous-cushings-syndrome-developing-drugs-treatment" title="Endogenous Cushing’s Syndrome: Developing Drugs for Treatment">Endogenous Cushing’s Syndrome: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>9/08/2023</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="351e6011-54a9-4fe6-a400-bd7133930b8b" href="/regulatory-information/search-fda-guidance-documents/post-warning-letter-meetings-under-gdufa" title="Post-Warning Letter Meetings Under GDUFA">Post-Warning Letter Meetings Under GDUFA</a></td>
			<td>Draft</td>
			<td>9/05/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="2566a8f4-437f-4ac4-862f-a18712f46e0b" href="/regulatory-information/search-fda-guidance-documents/wholesale-distributor-verification-requirement-saleable-returned-drug-product-and-dispenser-0" title="Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies">Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies</a></td>
			<td>Final</td>
			<td>9/01/2023</td>
		</tr><tr><td>Real World Data / Real World Evidence (RWD/RWE), Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b5d9e7fd-cf15-4fa2-b64c-98ead7379dd5" href="/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug" title="Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products">Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products</a></td>
			<td>Final</td>
			<td>8/30/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="82b55e64-6b4b-4805-bde5-28babd1d246a" href="/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-package-level-under-drug-supply-chain-security-act" title="Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act">Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act</a></td>
			<td>Final</td>
			<td>8/30/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d9c95391-a273-4235-ab18-68caed6498dc" href="/regulatory-information/search-fda-guidance-documents/enhanced-drug-distribution-security-requirements-under-section-582g1-federal-food-drug-and-cosmetic" title="Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies">Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies</a></td>
			<td>Final</td>
			<td>8/28/2023</td>
		</tr><tr><td>Biosimilars</td>
			<td>
			<p style="margin-bottom:11px"><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="54d8b768-673c-43ba-8b05-946449d197f2" href="/regulatory-information/search-fda-guidance-documents/classification-categories-certain-supplements-under-bsufa-iii" title="Classification Categories for Certain Supplements Under BsUFA III">Classification Categories for Certain Supplements Under BsUFA III</a></p>
			</td>
			<td>Draft</td>
			<td>8/11/2023</td>
		</tr><tr><td>Biosimilars</td>
			<td>
			<p style="margin-bottom:11px"><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3214ad64-1f9a-4d5d-9dbe-66645619ba4b" href="/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-sponsors-or-applicants-bsufa-products-guidance-industry" title="Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry">Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry</a></p>
			</td>
			<td>Draft</td>
			<td>8/11/2023</td>
		</tr><tr><td>User Fees</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bbc9c9a4-342b-4c78-b37d-a48a2520ddeb" href="/regulatory-information/search-fda-guidance-documents/pdufa-waivers-reductions-and-refunds-fixed-combinations-and-single-entity-versions-previously" title="PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR">PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR</a></td>
			<td>Draft</td>
			<td>8/03/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="be74c7a4-c7ef-490d-b3c2-e31faaf221f5" href="/regulatory-information/search-fda-guidance-documents/waivers-exceptions-and-exemptions-requirements-section-582-federal-food-drug-and-cosmetic-act" title="Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act">Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Final</td>
			<td>8/03/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="b3f4be04-944e-4f22-b1dd-f106fe534aa1" href="/regulatory-information/search-fda-guidance-documents/fixed-combinations-and-single-entity-versions-previously-approved-antiretrovirals-treatment-or" title="Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief">Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief</a></td>
			<td>Draft</td>
			<td>8/02/2023</td>
		</tr><tr><td>Drug Competition Action Plan, Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6360d6ce-b64a-40a4-886e-b53cafe34a55" href="/regulatory-information/search-fda-guidance-documents/cders-program-recognition-voluntary-consensus-standards-related-pharmaceutical-quality" title="CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality">CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality</a></td>
			<td>Final</td>
			<td>7/26/2023</td>
		</tr><tr><td>FDAAA</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5c5dff8c-0522-47b4-84f7-7b57601a6415" href="/regulatory-information/search-fda-guidance-documents/postmarketing-studies-and-clinical-trials-determining-good-cause-noncompliance-section-505o3eii" title="Postmarketing Studies and Clinical Trials:  Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act">Postmarketing Studies and Clinical Trials: Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Draft</td>
			<td>7/14/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e54935dc-11f8-4d0f-8cf7-3792d02b2d2e" href="/regulatory-information/search-fda-guidance-documents/inborn-errors-metabolism-use-dietary-management-considerations-optimizing-and-standardizing-diet" title="Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development">Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development</a></td>
			<td>Draft</td>
			<td>7/12/2023</td>
		</tr><tr><td> </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="63a4452c-4ab0-4e11-bf78-c06b142cdc04" href="/regulatory-information/search-fda-guidance-documents/submitting-nonclinical-datasets-evaluation-rodent-carcinogenicity-studies-pharmaceuticals" title="Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals">Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals</a></td>
			<td>Final</td>
			<td>5/01/2021</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4f225efb-59a5-4123-b2c8-10bd8b5cdc38" href="/regulatory-information/search-fda-guidance-documents/chronic-rhinosinusitis-nasal-polyps-developing-drugs-treatment" title="Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment ">Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment</a></td>
			<td>Final</td>
			<td>6/29/2023</td>
		</tr><tr><td>Compounding</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0144903e-1a9f-4f39-9f19-515b0cffbd1a" href="/regulatory-information/search-fda-guidance-documents/prohibition-wholesaling-under-section-503b-federal-food-drug-and-cosmetic-act" title="Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act">Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Draft</td>
			<td>6/27/2023</td>
		</tr><tr><td>Advertising</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c1b4f47d-89ea-47fb-9a3c-baa6b55a8bb4" href="/regulatory-information/search-fda-guidance-documents/presenting-quantitative-efficacy-and-risk-information-direct-consumer-dtc-promotional-labeling-and" title="Presenting Quantitative Efficacy and Risk Information in  Direct-to-Consumer (DTC) Promotional Labeling and Advertisements">Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer (DTC) Promotional Labeling and Advertisements</a></td>
			<td>Final</td>
			<td>6/27/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bff0a5b8-f6d7-47e2-bac4-301625cd7932" href="/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations" title="Psychedelic Drugs: Considerations for Clinical Investigations">Psychedelic Drugs: Considerations for Clinical Investigations</a></td>
			<td>Draft</td>
			<td>6/23/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d395f443-19ec-4aae-880f-6362d68a639a" href="/regulatory-information/search-fda-guidance-documents/formal-dispute-resolution-and-administrative-hearings-final-administrative-orders-under-section-505g" title="Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act">Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Draft</td>
			<td>6/23/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="65befebd-1d72-432e-be3b-4c661abdab4e" href="/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry" title="Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry">Clinical Drug Interaction Studies with the Combined Oral Contraceptives Guidance for Industry</a></td>
			<td>Final</td>
			<td>6/8/2023</td>
		</tr><tr><td>ICH-Efficacy</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8c201b8b-180b-429b-861c-9150bc4b7617" href="/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp" title="E6(R3) GOOD CLINICAL PRACTICE (GCP)">E6(R3) GOOD CLINICAL PRACTICE (GCP)</a></td>
			<td>Draft</td>
			<td>6/7/2023</td>
		</tr><tr><td>Generic Drugs</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bb688f7e-2777-413a-8b47-668ae424c20a" href="/regulatory-information/search-fda-guidance-documents/cover-letter-attachments-controlled-correspondences-and-anda-submissions" title="Cover Letter Attachments for Controlled Correspondences and ANDA Submissions">Cover Letter Attachments for Controlled Correspondences and ANDA Submissions</a></td>
			<td>Final</td>
			<td>6/05/2023</td>
		</tr><tr><td>Pharmacology/Toxicology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="87ffefcb-0c5b-4159-af1b-4a9c35436de0" href="/regulatory-information/search-fda-guidance-documents/nonclinical-evaluation-immunotoxic-potential-pharmaceuticals" title="Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals">Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals</a></td>
			<td>Final</td>
			<td>6/05/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="90acf941-322a-4ef9-a472-18771772b3ef" href="/regulatory-information/search-fda-guidance-documents/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-treatment" title="Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment">Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment</a></td>
			<td>Draft</td>
			<td>6/02/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8fd75402-e7e3-40f6-b813-6a4686a430ca" href="/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry" title="Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry">Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry</a></td>
			<td>Final</td>
			<td>6/02/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1a74e23b-6c48-43b2-aba6-717f23996e7d" href="/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-preventive-treatment" title="Migraine:  Developing Drugs for Preventive Treatment">Migraine: Developing Drugs for Preventive Treatment</a></td>
			<td>Draft</td>
			<td>6/01/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="139f67e1-cbd3-41d6-9de7-95a86fcaaf75" href="/regulatory-information/search-fda-guidance-documents/diabetes-mellitus-efficacy-endpoints-clinical-trials-investigating-antidiabetic-drugs-and-biological" title="Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products">Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products</a></td>
			<td>Draft</td>
			<td>5/26/2023</td>
		</tr><tr><td> </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="81fb4c0d-0818-43e1-94a2-3bb63e058a83" href="/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products" title="Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products">Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products</a></td>
			<td>Final</td>
			<td>5/25/2023</td>
		</tr><tr><td>Electronic Submissions</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f0e928e2-8c83-4b27-9bf5-6ede4f78b237" href="/regulatory-information/search-fda-guidance-documents/study-data-technical-conformance-guide-technical-specifications-document" title="Study Data Technical Conformance Guide - Technical Specifications Document">Study Data Technical Conformance Guide - Technical Specifications Document</a></td>
			<td>Final</td>
			<td>5/24/2023</td>
		</tr><tr><td>Pharmacology/Toxicology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d673a30b-a2de-462e-a7f9-e2fa477067ad" href="/regulatory-information/search-fda-guidance-documents/use-whole-slide-imaging-nonclinical-toxicology-studies-questions-and-answers" title="Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers">Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers</a></td>
			<td>Final</td>
			<td>5/25/2023</td>
		</tr><tr><td>Pharmacology/Toxicology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c8bd9041-7406-4b07-9543-eaf6e8d6246d" href="/regulatory-information/search-fda-guidance-documents/generally-accepted-scientific-knowledge-applications-drug-and-biological-products-nonclinical" title="Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products:  Nonclinical Information">Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products: Nonclinical Information</a></td>
			<td>Draft</td>
			<td>5/25/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="864fff55-1730-4645-86c1-af19b3b7c6e2" href="/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-under-pediatric-research-equity-act-and-best-pharmaceuticals-children-act" title="Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act:  Scientific Considerations">Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations</a></td>
			<td>Draft</td>
			<td>5/18/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1d06b86d-bbe5-4d90-a615-b821c7c165a0" href="/regulatory-information/search-fda-guidance-documents/pediatric-drug-development-regulatory-considerations-complying-pediatric-research-equity-act-and" title="Pediatric Drug Development:  Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act">Pediatric Drug Development: Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act</a></td>
			<td>Draft</td>
			<td>5/18/2023</td>
		</tr><tr><td>Compliance</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="84aeceac-138c-44ca-8a34-fa40f12446a6" href="/regulatory-information/search-fda-guidance-documents/testing-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol" title="Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol ">Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol</a> </td>
			<td>Final</td>
			<td>5/8/2023</td>
		</tr><tr><td>User Fees</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3aa2c7a9-bee7-4668-af28-7a425f2fa528" href="/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-prescription-drug-user-fee-amendments-2022" title="Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022">Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022</a></td>
			<td>Final</td>
			<td>5/1/2023</td>
		</tr><tr><td>ICH - Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3d82625c-20db-4dcd-b18d-06c664c8cbbd" href="/regulatory-information/search-fda-guidance-documents/q9r1-quality-risk-management" title="Q9(R1) Quality Risk Management">Q9(R1) Quality Risk Management</a></td>
			<td>Final</td>
			<td>5/3/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="69af073d-dd6b-4265-a3d7-62ea2fbf33e1" href="/regulatory-information/search-fda-guidance-documents/decentralized-clinical-trials-drugs-biological-products-and-devices" title="Decentralized Clinical Trials for Drugs, Biological Products, and Devices">Decentralized Clinical Trials for Drugs, Biological Products, and Devices</a></td>
			<td>Draft</td>
			<td>5/3/2023</td>
		</tr><tr><td>ICH-Safety</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1bb74db4-89d0-4649-b4af-b9b5b192c4d3" href="/regulatory-information/search-fda-guidance-documents/s12-nonclinical-biodistribution-considerations-gene-therapy-products" title="S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS">S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS</a></td>
			<td>Final</td>
			<td>5/1/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="607e4f1a-e54d-48fd-b7b5-8f424b8c13f7" href="/regulatory-information/search-fda-guidance-documents/smoking-cessation-and-related-indications-developing-nicotine-replacement-therapy-drug-products" title="Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products">Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products</a></td>
			<td>Final</td>
			<td>5/1/2023</td>
		</tr><tr><td>Animal Rule</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="05b6638a-314e-4fab-833a-fb8792f15c1f" href="/regulatory-information/search-fda-guidance-documents/acute-radiation-syndrome-developing-drugs-prevention-and-treatment" title="Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment">Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment</a></td>
			<td>Draft</td>
			<td>4/20/2023</td>
		</tr><tr><td>Over the Counter</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="69e52521-fcb6-4bc3-b75f-612e05ac3bc6" href="/regulatory-information/search-fda-guidance-documents/over-counter-monograph-order-requests-format-and-content" title="Over-the-Counter Monograph Order Requests: Format and Content">Over-the-Counter Monograph Order Requests: Format and Content</a></td>
			<td>Draft</td>
			<td>4/13/2023</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e5a4126b-6e19-4518-ae86-8f58db28dcc6" href="/regulatory-information/search-fda-guidance-documents/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas" title="Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs">Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs</a></td>
			<td>Draft</td>
			<td>4/13/2023</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="04f8d53c-610d-457a-9730-cc7d45bd92bf" href="/regulatory-information/search-fda-guidance-documents/assessing-adhesion-transdermal-and-topical-delivery-systems-andas-draft-guidance-industry" title="Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry">Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry</a></td>
			<td>Draft</td>
			<td>4/13/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1283d1dc-af89-4220-85bb-dd450431ca68" href="/regulatory-information/search-fda-guidance-documents/risk-based-approach-monitoring-clinical-investigations-questions-and-answers" title="A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers">A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers</a></td>
			<td>Final</td>
			<td>4/12/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d40918d4-a62a-45bb-85e1-3f67d35d4bb5" href="/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory" title="Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making">Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making</a></td>
			<td>Draft</td>
			<td>4/5/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="768958d2-f64c-4ed2-b290-bf499646dce7" href="/regulatory-information/search-fda-guidance-documents/notifying-fda-discontinuance-or-interruption-manufacturing-finished-products-or-active" title="Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&amp;C Act">Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&amp;C Act</a></td>
			<td>Draft</td>
			<td>4/5/2023</td>
		</tr><tr><td>Electronic Submissions</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9b8340ba-3399-49bb-a057-58f5c78895c2" href="/regulatory-information/search-fda-guidance-documents/identification-medicinal-products-implementation-and-use" title="Identification of Medicinal Products —  Implementation and Use">Identification of Medicinal Products — Implementation and Use</a></td>
			<td>Final</td>
			<td>3/30/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6aecfb02-87e2-4ad3-8ade-a2785299d3b7" href="/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-0" title="Pharmacogenomic Data Submissions">Pharmacogenomic Data Submissions</a></td>
			<td>Draft</td>
			<td>3/17/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e72ad660-311b-47c5-ad2a-c4fbc65a2089" href="/regulatory-information/search-fda-guidance-documents/development-local-anesthetic-drug-products-prolonged-duration-effect" title="Development of Local Anesthetic Drug Products With Prolonged Duration of Effect">Development of Local Anesthetic Drug Products With Prolonged Duration of Effect</a></td>
			<td>Draft</td>
			<td>3/15/2023</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6e699c2f-84d4-4af1-ac3f-74d2f8de1189" href="/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions" title="Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations:  Questions and Answers">Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers</a></td>
			<td>Draft</td>
			<td>3/15/2023</td>
		</tr><tr><td>ICH - Quality </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d5e7f719-9c8e-4cce-94d4-be12383f5179" href="/regulatory-information/search-fda-guidance-documents/q13-continuous-manufacturing-drug-substances-and-drug-products" title="Q13 Continuous Manufacturing of Drug Substances and Drug Products">Q13 Continuous Manufacturing of Drug Substances and Drug Products</a></td>
			<td>Final</td>
			<td>3/1/2023</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0056e8d3-66a3-46cd-b517-6f9d07b18615" href="/regulatory-information/search-fda-guidance-documents/potency-assay-considerations-monoclonal-antibodies-and-other-therapeutic-proteins-targeting-viral" title="Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens">Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens</a></td>
			<td>Draft</td>
			<td>3/1/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="da7641ad-6b1e-4282-8706-b2f659ac8117" href="/regulatory-information/search-fda-guidance-documents/neovascular-age-related-macular-degeneration-developing-drugs-treatment" title="Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment">Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>2/24/2023</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="a524d09f-07ba-4e30-b8e4-780f64d0597c" href="/regulatory-information/search-fda-guidance-documents/product-specific-guidance-meetings-between-fda-and-anda-applicants-under-gdufa" title="Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA">Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA</a></td>
			<td>Draft</td>
			<td>2/17/2023</td>
		</tr><tr><td>ICH - Multidisciplinary</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bcb58d81-bb7a-4ff0-bd6e-a33d5e3ad8ab" href="/regulatory-information/search-fda-guidance-documents/m13a-bioequivalence-immediate-release-solid-oral-dosage-forms" title="M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms">M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms</a></td>
			<td>Draft</td>
			<td>1/31/2023</td>
		</tr><tr><td>Real World Data/Real World Evidence (RWD/RWE)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="44aff149-aa6e-4255-9fe9-fd5f81011771" href="/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products" title="Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products">Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products</a></td>
			<td>Draft</td>
			<td>1/31/2023</td>
		</tr><tr><td>Clinical - Pharmacology</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e6175018-8885-4a15-ab68-e2121364d810" href="/regulatory-information/search-fda-guidance-documents/acromegaly-developing-drugs-treatment" title="Acromegaly:  Developing Drugs for Treatment">Acromegaly: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>1/30/2023</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c1acfc0a-2df8-42cb-a079-307290ab5b44" href="/regulatory-information/search-fda-guidance-documents/cannabis-and-cannabis-derived-compounds-quality-considerations-clinical-research-guidance-industry" title="Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry">Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry</a></td>
			<td>Final</td>
			<td>1/23/2023</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="7cda9794-2f19-4ca0-82c7-3fd8f6f57236" href="/regulatory-information/search-fda-guidance-documents/mpox-development-drugs-and-biological-products-guidance-industry" title="Mpox: Development of Drugs and Biological Products; Guidance for Industry">Mpox: Development of Drugs and Biological Products</a></td>
			<td>Draft</td>
			<td>1/19/2023</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d50ab8a1-8308-4d9e-8f4c-76d72771fb2b" href="/regulatory-information/search-fda-guidance-documents/dosage-and-administration-section-labeling-human-prescription-drug-and-biological-products-content" title="Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format">Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format</a></td>
			<td>Draft</td>
			<td>1/12/2023</td>
		</tr><tr><td>Drug Safety</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5bc0240d-3502-481f-a413-32182cfc13b2" href="/regulatory-information/search-fda-guidance-documents/format-and-content-rems-document-guidance-industry" title="Format and Content of a REMS Document Guidance for Industry">Format and Content of a REMS Document</a></td>
			<td>Final</td>
			<td>1/4/2023</td>
		</tr><tr><td>ICH - Multidisciplinary</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="83f123db-686e-42f7-b6fd-6439e64d7938" href="/regulatory-information/search-fda-guidance-documents/m11-template-clinical-electronic-structured-harmonised-protocol" title="M11 Template: Clinical Electronic Structured Harmonised Protocol">M11 Template: Clinical Electronic Structured Harmonised Protocol</a></td>
			<td>Draft</td>
			<td>12/21/2022</td>
		</tr><tr><td>ICH - Multidisciplinary</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d450e0c8-4906-4287-8b8e-169a6642bf17" href="/regulatory-information/search-fda-guidance-documents/m11-technical-specification-clinical-electronic-structured-harmonised-protocol" title="M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol">M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol</a></td>
			<td>Draft</td>
			<td>12/21/2022</td>
		</tr><tr><td>ICH - Multidisciplinary</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e4f01462-c8bf-4c45-944e-0f96e1af41e2" href="/regulatory-information/search-fda-guidance-documents/m11-clinical-electronic-structured-harmonised-protocol" title="M11 Clinical Electronic Structured Harmonised Protocol">M11 Clinical Electronic Structured Harmonised Protocol</a></td>
			<td>Draft</td>
			<td>12/21/2022</td>
		</tr><tr><td>Generic Drugs</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="2adb9c12-113a-4258-926e-f8d6dd6df749" href="/regulatory-information/search-fda-guidance-documents/controlled-correspondence-related-generic-drug-development" title="Controlled Correspondence Related to Generic Drug Development">Controlled Correspondence Related to Generic Drug Development</a></td>
			<td>Draft</td>
			<td>12/21/2022</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d801f64d-e710-4f0c-b084-ed282c45fde9" href="/regulatory-information/search-fda-guidance-documents/hypertension-indication-drug-labeling-cardiovascular-outcome-claims" title="Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims">Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims</a></td>
			<td>Final</td>
			<td>12/15/2022</td>
		</tr><tr><td>Clinical-Antimicrobial</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="cff3d4f2-8b15-4be9-8bc4-d45bf2abae29" href="/regulatory-information/search-fda-guidance-documents/pulmonary-tuberculosis-developing-drugs-treatment" title="Pulmonary Tuberculosis: Developing Drugs for Treatment">Pulmonary Tuberculosis: Developing Drugs for Treatment</a></td>
			<td>Draft</td>
			<td>12/14/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ff1170d0-039a-4381-98ff-2299a9baf7b0" href="/regulatory-information/search-fda-guidance-documents/failure-respond-anda-complete-response-letter-within-regulatory-timeframe-guidance-industry" title="Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry">Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry</a></td>
			<td>Final</td>
			<td>12/14/2022</td>
		</tr><tr><td>Compliance</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="65960b54-b1d5-46b8-b1db-770444d1db6c" href="/regulatory-information/search-fda-guidance-documents/homeopathic-drug-products-guidance-fda-staff-and-industry" title="Homeopathic Drug Products Guidance for FDA Staff and Industry">Drug Products Labeled as Homeopathic Guidance for FDA Staff and Industry</a></td>
			<td>Final</td>
			<td>12/7/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3cad1c7a-049e-4e62-a7f5-fec23f6cf838" href="/regulatory-information/search-fda-guidance-documents/small-volume-parenteral-drug-products-and-pharmacy-bulk-packages-parenteral-nutrition-aluminum" title="Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations">Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations</a></td>
			<td>Draft</td>
			<td>12/6/2022</td>
		</tr><tr><td>ICH-Safety</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8d707796-97fd-4217-917f-0c8b27c9943b" href="/regulatory-information/search-fda-guidance-documents/e19-selective-approach-safety-data-collection-specific-late-stage-pre-approval-or-post-approval" title="E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials">E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials</a></td>
			<td>Final</td>
			<td>12/5/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1d36c68e-e4c5-46be-9ef6-22c3e2ef9a3a" href="/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence-0" title="Statistical Approaches to Establishing Bioequivalence">Statistical Approaches to Establishing Bioequivalence</a></td>
			<td>Draft</td>
			<td>12/2/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8aa6e21b-5e97-4487-a83e-14cc50372b99" href="/regulatory-information/search-fda-guidance-documents/andas-pre-submission-facility-correspondence-related-prioritized-generic-drug-submissions" title="ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions">ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions</a></td>
			<td>Draft</td>
			<td>12/2/2022</td>
		</tr><tr><td>Clinical-Antimicrobial</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="d5f12451-887e-4c1c-9f25-adc6244a15e9" href="/regulatory-information/search-fda-guidance-documents/compounding-certain-beta-lactam-products-shortage-under-section-503a-federal-food-drug-and-cosmetic" title="Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act">Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food, Drug, and Cosmetic Act</a></td>
			<td>Final</td>
			<td>11/18/2022</td>
		</tr><tr><td>ICH-Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6f1f6ceb-e7ef-4d42-9748-6be9ad7e1c6d" href="/regulatory-information/search-fda-guidance-documents/q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-or-animal-origin" title="Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin">Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human or Animal Origin</a></td>
			<td>Draft</td>
			<td>11/10/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="fe2d2521-ec30-4456-bed1-86ae237270fb" href="/regulatory-information/search-fda-guidance-documents/sameness-evaluations-anda-active-ingredients" title="Sameness Evaluations in an ANDA — Active Ingredients">Sameness Evaluations in an ANDA — Active Ingredients</a></td>
			<td>Draft</td>
			<td>11/8/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8100d4e0-8135-4944-b30e-f2a132110dda" href="/regulatory-information/search-fda-guidance-documents/m10-bioanalytical-method-validation-and-study-sample-analysis" title="M10 Bioanalytical Method Validation and Study Sample Analysis">M10 Bioanalytical Method Validation and Study Sample Analysis</a></td>
			<td>Final</td>
			<td>11/4/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4c5ede38-6730-4267-8491-f0d84c0203b4" href="/regulatory-information/search-fda-guidance-documents/cross-labeling-oncology-drugs-combination-regimens" title="Cross Labeling Oncology Drugs in Combination Regimens">Cross Labeling Oncology Drugs in Combination Regimens</a></td>
			<td>Final</td>
			<td>11/2/2022</td>
		</tr><tr><td>ICH-Safety</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ad9b3017-c2c8-492b-8e46-dbc426493eef" href="/regulatory-information/search-fda-guidance-documents/s1br1-addendum-s1b-testing-carcinogenicity-pharmaceuticals" title="S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals">S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals</a></td>
			<td>Final</td>
			<td>11/2/2022</td>
		</tr><tr><td>User Fees</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8b2fea9c-3e14-4653-bfe8-826376c2541c" href="/regulatory-information/search-fda-guidance-documents/assessing-user-fees-under-over-counter-monograph-drug-user-fee-program" title="Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program">Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program</a></td>
			<td>Draft</td>
			<td>11/1/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="21f8a7b1-79ea-4498-aaba-99e1d00c259c" href="/regulatory-information/search-fda-guidance-documents/measuring-growth-and-evaluating-pubertal-development-pediatric-clinical-trials-draft-guidance" title="Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability ">Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials</a></td>
			<td>Draft</td>
			<td>10/31/2022</td>
		</tr><tr><td>Clinical - Antimicrobial</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="8e53a7dd-c33d-46ae-a6c5-70210b57cb46" href="/regulatory-information/search-fda-guidance-documents/clostridioides-difficile-infection-developing-drugs-treatment-reduction-recurrence-and-prevention" title="Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention">Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention</a></td>
			<td>Draft</td>
			<td>10/27/2022</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="09594f59-394e-4ff3-adce-b125197313d1" href="/regulatory-information/search-fda-guidance-documents/planning-effects-high-absenteeism-ensure-availability-medically-necessary-drug-products-0" title="Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products">Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products</a></td>
			<td>Final</td>
			<td>10/27/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="7dbf7525-9e7b-48d5-8ca0-db29073e893b" href="/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-0" title="Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence">Topical Dermatologic Corticosteroids: In Vivo Bioequivalence</a></td>
			<td>Draft </td>
			<td>10/21/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f2f62a70-f993-4984-8291-edaa3944f466" href="/regulatory-information/search-fda-guidance-documents/in-vitro-release-test-studies-topical-drug-products-submitted-andas" title="In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs">In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4c4f0a69-0696-4de8-b68a-08d463284c93" href="/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas" title="In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs">In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bf9cc680-f337-4b88-b912-0a979a6bc8a7" href="/regulatory-information/search-fda-guidance-documents/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas" title="Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs">Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Biostatistics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bdc0817d-cd4a-4ed2-a3f4-23ca1eb045cd" href="/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry" title="Multiple Endpoints in Clinical Trials Guidance for Industry">Multiple Endpoints in Clinical Trials</a></td>
			<td>Final</td>
			<td>10/20/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5c4495ef-3316-4ece-8261-8a34bf663860" href="/regulatory-information/search-fda-guidance-documents/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda" title="Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA">Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA</a></td>
			<td>Final</td>
			<td>10/13/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="28cfb85b-8949-48ac-a4f3-06af635f8be6" href="/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry" title="Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry">Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA</a> </td>
			<td>Final</td>
			<td>10/5/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4172f3c4-3255-4185-bc68-45fa4443640a" href="/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies" title="Competitive Generic Therapies">Competitive Generic Therapies</a></td>
			<td>Final</td>
			<td>10/5/2022</td>
		</tr><tr><td>Generics</td>
			<td><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-readiness-goal-date-decisions-under-gdufa">Facility Readiness: Goal Date Decisions Under GDUFA</a></td>
			<td>Draft</td>
			<td>10/3/2022</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa">Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA</a></td>
			<td>Draft</td>
			<td>10/3/2022</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c9da9da1-7209-4fab-acb3-afcfc515efaa" href="/regulatory-information/search-fda-guidance-documents/size-shape-and-other-physical-attributes-generic-tablets-and-capsules" title="Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules">Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules</a></td>
			<td>Final</td>
			<td>10/3/2022</td>
		</tr><tr><td>Electronic Submissions</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="deb5ff64-2ed2-4855-90b8-b0d8bcf2ff6e" href="/regulatory-information/search-fda-guidance-documents/providing-over-counter-monograph-submissions-electronic-format" title="Providing Over-the-Counter Monograph Submissions in Electronic Format">Providing Over-the-Counter Monograph Submissions in Electronic Format</a></td>
			<td>Draft</td>
			<td>9/27/2022</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="491c45e2-5031-4a1d-bea6-48188338c2e6" href="/regulatory-information/search-fda-guidance-documents/exemption-and-exclusion-certain-requirements-drug-supply-chain-security-act-distribution-fda" title="Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry">Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry</a></td>
			<td>Final</td>
			<td>9/22/2022</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e3496f68-e22b-4954-ab17-a39ef6324b54" href="/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization" title="How To Obtain a Covered Product Authorization">How To Obtain a Covered Product Authorization</a></td>
			<td>Draft</td>
			<td>9/21/2022</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ab73cf83-f735-406b-9131-4f607c996e6e" href="/regulatory-information/search-fda-guidance-documents/statement-identity-and-strength-content-and-format-labeling-human-nonprescription-drug-products" title="Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products">Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products</a></td>
			<td>Draft</td>
			<td>9/8/2022</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="7db12240-c382-48f2-9ff5-28f983509671" href="/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug" title="Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products">Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products</a></td>
			<td>Draft</td>
			<td>9/8/2022</td>
		</tr><tr><td>Real World Data/Real World Evidence (RWD/RWE)<br />
			Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="046578af-caed-4f89-9389-68cfd26cee02" href="/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products" title="Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products">Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products</a></td>
			<td>Final</td>
			<td>9/8/2022</td>
		</tr><tr><td> </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1f49f675-8b36-46a5-9944-e788bf6c0da8" href="/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation" title="E11A Pediatric Extrapolation">E11A Pediatric Extrapolation</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr><tr><td>ICH-Multidisciplinary </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9cfe2189-3843-4e3c-8f68-a1cab812569b" href="/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies" title="M12 Drug Interaction Studies">M12 Drug Interaction Studies</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr><tr><td>ICH-Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="62401e8e-4b95-44ce-8faf-6e75cf76569d" href="/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development" title="Q14 Analytical Procedure Development">Q14 Analytical Procedure Development</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr><tr><td>ICH-Quality</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="0689a771-77b7-4b68-b42f-dcdc01ab9de9" href="/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures" title="Q2(R2) Validation of Analytical Procedures">Q2(R2) Validation of Analytical Procedures</a><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="62401e8e-4b95-44ce-8faf-6e75cf76569d" href="/regulatory-information/search-fda-guidance-documents/q14-analytical-procedure-development" title="Q14 Analytical Procedure Development">Q14 Analytical Procedure Development</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr><tr><td>ICH-Efficacy, ICH-Safety</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9927dcf2-b5b8-4e63-8c61-7ea0202e399d" href="/regulatory-information/search-fda-guidance-documents/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic" title="E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers ">E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers</a></td>
			<td>Final</td>
			<td>8/26/2022</td>
			<td> </td>
			<td> </td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="f2f62a70-f993-4984-8291-edaa3944f466" href="/regulatory-information/search-fda-guidance-documents/in-vitro-release-test-studies-topical-drug-products-submitted-andas" title="In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs">In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4c4f0a69-0696-4de8-b68a-08d463284c93" href="/regulatory-information/search-fda-guidance-documents/in-vitro-permeation-test-studies-topical-drug-products-submitted-andas" title="In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs">In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bf9cc680-f337-4b88-b912-0a979a6bc8a7" href="/regulatory-information/search-fda-guidance-documents/physicochemical-and-structural-q3-characterization-topical-drug-products-submitted-andas" title="Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs">Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs</a></td>
			<td>Draft</td>
			<td>10/21/2022</td>
		</tr><tr><td>Biostatistics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="bdc0817d-cd4a-4ed2-a3f4-23ca1eb045cd" href="/regulatory-information/search-fda-guidance-documents/multiple-endpoints-clinical-trials-guidance-industry" title="Multiple Endpoints in Clinical Trials Guidance for Industry">Multiple Endpoints in Clinical Trials</a></td>
			<td>Final</td>
			<td>10/20/2022</td>
		</tr><tr><td>Clinical - Medical</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="5c4495ef-3316-4ece-8261-8a34bf663860" href="/regulatory-information/search-fda-guidance-documents/comparability-protocols-postapproval-changes-chemistry-manufacturing-and-controls-information-nda" title="Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA">Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA</a></td>
			<td>Final</td>
			<td>10/13/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="28cfb85b-8949-48ac-a4f3-06af635f8be6" href="/regulatory-information/search-fda-guidance-documents/formal-meetings-between-fda-and-anda-applicants-complex-products-under-gdufa-guidance-industry" title="Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry">Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA</a> </td>
			<td>Final</td>
			<td>10/5/2022</td>
		</tr><tr><td>Generics</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4172f3c4-3255-4185-bc68-45fa4443640a" href="/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies" title="Competitive Generic Therapies">Competitive Generic Therapies</a></td>
			<td>Final</td>
			<td>10/5/2022</td>
		</tr><tr><td>Generics</td>
			<td><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/facility-readiness-goal-date-decisions-under-gdufa">Facility Readiness: Goal Date Decisions Under GDUFA</a></td>
			<td>Draft</td>
			<td>10/3/2022</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa">Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA</a></td>
			<td>Draft</td>
			<td>10/3/2022</td>
		</tr><tr><td>Pharmaceutical Quality/Chemistry, Manufacturing, and Controls (CMC)</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="c9da9da1-7209-4fab-acb3-afcfc515efaa" href="/regulatory-information/search-fda-guidance-documents/size-shape-and-other-physical-attributes-generic-tablets-and-capsules" title="Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules">Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules</a></td>
			<td>Final</td>
			<td>10/3/2022</td>
		</tr><tr><td>Electronic Submissions</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="deb5ff64-2ed2-4855-90b8-b0d8bcf2ff6e" href="/regulatory-information/search-fda-guidance-documents/providing-over-counter-monograph-submissions-electronic-format" title="Providing Over-the-Counter Monograph Submissions in Electronic Format">Providing Over-the-Counter Monograph Submissions in Electronic Format</a></td>
			<td>Draft</td>
			<td>9/27/2022</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="491c45e2-5031-4a1d-bea6-48188338c2e6" href="/regulatory-information/search-fda-guidance-documents/exemption-and-exclusion-certain-requirements-drug-supply-chain-security-act-distribution-fda" title="Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry">Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry</a></td>
			<td>Final</td>
			<td>9/22/2022</td>
		</tr><tr><td>Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="e3496f68-e22b-4954-ab17-a39ef6324b54" href="/regulatory-information/search-fda-guidance-documents/how-obtain-covered-product-authorization" title="How To Obtain a Covered Product Authorization">How To Obtain a Covered Product Authorization</a></td>
			<td>Draft</td>
			<td>9/21/2022</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ab73cf83-f735-406b-9131-4f607c996e6e" href="/regulatory-information/search-fda-guidance-documents/statement-identity-and-strength-content-and-format-labeling-human-nonprescription-drug-products" title="Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products">Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products</a></td>
			<td>Draft</td>
			<td>9/8/2022</td>
		</tr><tr><td>Labeling</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="7db12240-c382-48f2-9ff5-28f983509671" href="/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug" title="Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products">Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products</a></td>
			<td>Draft</td>
			<td>9/8/2022</td>
		</tr><tr><td>Real World Data/Real World Evidence (RWD/RWE)<br />
			Administrative/Procedural</td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="046578af-caed-4f89-9389-68cfd26cee02" href="/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products" title="Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products">Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products</a></td>
			<td>Final</td>
			<td>9/8/2022</td>
		</tr><tr><td> </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="1f49f675-8b36-46a5-9944-e788bf6c0da8" href="/regulatory-information/search-fda-guidance-documents/e11a-pediatric-extrapolation" title="E11A Pediatric Extrapolation">E11A Pediatric Extrapolation</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr><tr><td>ICH-Multidisciplinary </td>
			<td><a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9cfe2189-3843-4e3c-8f68-a1cab812569b" href="/regulatory-information/search-fda-guidance-documents/m12-drug-interaction-studies" title="M12 Drug Interaction Studies">M12 Drug Interaction Studies</a></td>
			<td>Draft</td>
			<td>8/26/2022</td>
		</tr></tbody></table></div>


<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<script type='text/javascript'>
  (function(){var g=function(e,h,f,g){
    this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
    this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
    this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
    this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}};
    this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};};
              try{(new g(100,"r","QSI_S_ZN_6FpQ8uiCQiPh6SN","https://zn6fpq8uicqiph6sn-fdawebcx.gov1.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_6FpQ8uiCQiPh6SN")).start()}catch(i){}})();
</script>
<div id="ZN_6FpQ8uiCQiPh6SN"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END WEBSITE FEEDBACK SNIPPET-->
<div class="content-feedback inset-column">&nbsp;</div>
<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->



              
                                            
              
            </div>

                                                                                  <aside class="col-md-2 col-md-push-2" role="complementary">
                  <section id="block-entityviewcontent-4" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

<div class="region region-">
  <aside class="lcds-card lcds-card--border-top">
    <ul role="menu" class="lcds-description-list">
      
                            

























  <li role="menuitem" class="node-current-date lcds-description-list__item">
    <div>
      <h2 class="lcds-description-list__item-heading">Content current as of:</h2>
      <p class="lcds-description-list__item-text"><time datetime="2024-02-05T00:00:00Z">02/05/2024</time>
</p>
    </div>
  </li>
              
              
<li role="menuitem" class="lcds-description-list__item">  
	<div>
		
		 <h2 class="lcds-description-list__item-heading">Regulated Product(s)</h2>
		 <ul role="menu" class="lcds-metadata-list">
						  <li role="menuitem">Drugs</li>
			  			     			  						              
			
			
			
			
			
			
			
			
					</ul>
	 
			     
						       

			  
						  

			  
						 
	</div>
</li>   

    </ul>

  </aside>
</div>


  </section>


                </aside>
            

                                                                                <aside class="col-md-2 col-md-pull-10" role="complementary">
                  <section id="block-entityviewcontent-3" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

        <div class="region region-">
        <nav id="section-nav"class="lcds-card lcds-section-nav lcds-section-nav--side hidden-xs hidden-sm">
      <ul class="lcds-section-nav__list lcds-section-nav--side__list">
        <li>

                    <a href="/drugs/guidance-compliance-regulatory-information/guidances-drugs" class="lcds-section-nav__link lcds-section-nav--side__link lcds-section-nav__parent-link lcds-section-nav--side__parent-link">
                                        Guidances | Drugs
                      </a>

          
                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_4 js-view-dom-id-a09bbe4eef58dadca1487ca63dd954d4ce65b256dd52741ffd4fb1df3866af4c">
  
    
      
  
      <div class="item-list">
  
  <ul class="lcds-section-nav__active lcds-section-nav__list lcds-section-nav--side__list">

          <li><a href="/drugs/guidances-drugs/product-specific-guidances-generic-drug-development" class="lcds-section-nav__link lcds-section-nav--side__link">Product-Specific Guidances for Generic Drug Development</a></li>
          <li><a href="/drugs/guidances-drugs/guidance-snapshot-pilot" class="lcds-section-nav__link lcds-section-nav--side__link">Guidance Snapshot Pilot</a></li>
    
  </ul>

</div>


  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_1 js-view-dom-id-fde4f78179738e8f3751a187180ae31aee2fc7f3b5391f6cc881e10e01cb5a6e">
  
    
      
  
          </div>
</div>


        </li>
      </ul>
    </nav>
    </div>

  </section>


                </aside>
            
                 </article>        
      </main>

    </div>  </div>

                <div class="region region-subscribe">
    <section id="block-entityviewcontent-5" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

  </section>


  </div>

  
      <footer class="lcds-footer container-fluid">
        
    <div class="row lcds-footer__primary">
    <h2 id="footer-heading" class="sr-only">Footer Links</h2>
    <nav class="text-center">
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/about-website/fdagov-archive" >FDA Archive</a></li>
          <li><a href="/about-fda" >About FDA</a></li>
          <li><a href="/about-fda/about-website/internet-accessibility" >Accessibility</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/visitor-information" >Visitor Information</a> </li>
          <li><a href="/about-fda/about-website/website-policies" >Website Policies / Privacy</a></li>
          <li><a href="/about-fda/jobs-and-training-fda/no-fear-act" >No FEAR Act</a></li>
          <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure Policy</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/regulatory-information/freedom-information" title="Freedom of Information Act">FOIA</a></li>
          <li><a href="https://www.hhs.gov/" title="Health and Human Services" target="_blank">HHS.gov</a></li>
          <li><a href="https://www.usa.gov/" target="_blank">USA.gov</a></li>
        </ul>
      </div>
    </nav>
  </div>
    <div class="row lcds-footer__secondary">
    <div class="col-sm-12 col-md-6 col-lg-4 lcds-footer__social-links">
      <a href="/about-fda/contact-fda" class="btn btn-default btn-md">Contact FDA</a>
      <a href="https://www.facebook.com/FDA" title="Follow FDA on Facebook" class="no-disclaimer"> 
        <span class="fa fa-facebook fa-2x" aria-hidden="true">
          <span class="sr-only">Follow FDA on Facebook</span> 
        </span>
      </a>
      <a href="https://x.com/US_FDA" title="Follow FDA on X" class="no-disclaimer">
        <svg class="icon-svg-inline fa-2x" aria-hidden="true">
          <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter">
        </svg>
        <span class="sr-only">Follow FDA on X</span>
      </a>
      <a href="https://instagram.com/FDA" title="Follow FDA on Instagram" class="no-disclaimer">
        <span class="fa fa-instagram fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on Instagram</span>
        </span>
      </a>
      <br class='visible-xs-inline'/>
      <a href="https://www.linkedin.com/company/fda/" title="Follow FDA on LinkedIn" class="no-disclaimer">
        <span class="fa fa-linkedin fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on LinkedIn</span>
        </span>
      </a>
      <a href="https://youtube.com/@US_FDA" title="View FDA videos on YouTube" class="no-disclaimer">
        <span class="fa fa-youtube fa-2x" aria-hidden="true"> 
          <span class="sr-only">View FDA videos on YouTube</span>
        </span>
      </a>
      <a href="/about-fda/contact-fda/subscribe-podcasts-and-news-feeds" title="Subscribe to FDA RSS feeds">
        <span class="fa fa-rss fa-2x" aria-hidden="true">
          <span class="sr-only">Subscribe to FDA RSS feeds</span>
        </span>
      </a>
    </div>
    <a href="/" title="FDA Homepage">
        <div class="visible-lg-block col-lg-4 text-center lcds-footer__logo">
          <span class="sr-only">FDA Homepage</span>
        </div>
    </a>
    <div class="col-sm-12 col-md-6 col-lg-4 text-center lcds-footer__contact-number">
      <span class="fa fa-phone" aria-hidden="true"> </span> 
     <span class="sr-only">Contact Number</span>
      1-888-INFO-FDA (1-888-463-6332)
    </div>
  </div>
  
    <script type='text/javascript'>
  (function(){var g=function(e,h,f,g){
  this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
  this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
  this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
  this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
  this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
  try{(new g(100,"r","QSI_S_ZN_6FpQ8uiCQiPh6SN","https://zn6fpq8uicqiph6sn-fdawebcx.gov1.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_6FpQ8uiCQiPh6SN")).start()}catch(i){}})();
  </script><div id='ZN_6FpQ8uiCQiPh6SN'><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
  <!--END WEBSITE FEEDBACK SNIPPET-->
  

    </footer>
    <a href="" id="btn-top" class="btn btn-primary btn-top"><span class="sr-only">Back to </span>Top</a>
  
  </div>

    
    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","scriptPath":null,"pathPrefix":"","currentPath":"node\/386734","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"fda_ckeditor_enhancements":{"basePath":"modules\/custom\/fda_ckeditor_enhancements"},"google_analytics":{"account":"G-273DTKB5QW","trackOutbound":true,"trackMailto":true,"trackTel":true,"trackDownload":true,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip"},"bootstrap":{"forms_has_error_value_toggle":1,"modal_animation":1,"modal_backdrop":"true","modal_focus_input":1,"modal_keyboard":1,"modal_select_text":1,"modal_show":1,"modal_size":"","popover_enabled":1,"popover_animation":1,"popover_auto_close":1,"popover_container":"body","popover_content":"","popover_delay":"0","popover_html":0,"popover_placement":"right","popover_selector":"","popover_title":"","popover_trigger":"click"},"ajax":[],"user":{"uid":0,"permissionsHash":"3aef67b4ac7d861d8624bf1f7ab2bc9cfc56d3c25b7d709dc15466dfa996dfb0"}}</script>
<script src="/files/js/js_gnZiM1ZiraNd5nGJXRXDo_4Tc5gJ035eI4yxKB2ZQqU.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=preview&amp;include=eJxlUNFuwyAM_CFS9jJpf4MccCgacAy7rdKvX7JqNN1kyTrdyb6zl0COM74uZJcBzYKqdGNBYXvAJxOBmNlRpbxq8mL_EkZWUS52JmHTOl8T32zMmClPomtONf6jfU9NxcyAinZqtqHhyt3sifwnh6TojuuZqufCVcWS9-ghoTpF3APIGV09wtN0G54C6VZzZnmhf3ce9V0U-9NPBeGS-WGP0nLajR-ae3_7OJDbp6AVymIHGla-033l-Dw4UHuJOEJP455vZX-dMw"></script>

  </body>
</html>
